Home » Stocks » CLSD

Clearside Biomedical, Inc. (CLSD)

Stock Price: $3.45 USD 0.14 (4.23%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $3.55 +0.10 (2.90%) Mar 1, 7:54 PM
Market Cap 189.20M
Revenue (ttm) 9.83M
Net Income (ttm) -14.19M
Shares Out 46.98M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $3.45
Previous Close $3.31
Change ($) 0.14
Change (%) 4.23%
Day's Open 3.45
Day's Range 3.30 - 3.71
Day's Volume 490,012
52-Week Range 1.10 - 4.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

GlobeNewsWire - 6 days ago

ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

GlobeNewsWire - 1 week ago

ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

GlobeNewsWire - 3 weeks ago

- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -

Zacks Investment Research - 3 weeks ago

As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Zacks Investment Research - 1 month ago

Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 1 month ago

ALPHARETTA, Ga., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

GlobeNewsWire - 1 month ago

ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

Seeking Alpha - 1 month ago

Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.

Seeking Alpha - 1 month ago

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year wi...

Other stocks mentioned: AAPL, CAT, DIS, DOW, EIGR, INTC, JNJ, JPM, NKE, NVR, WMT
GlobeNewsWire - 3 months ago

ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pre...

GlobeNewsWire - 3 months ago

ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

Seeking Alpha - 3 months ago

Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® On...

GlobeNewsWire - 4 months ago

ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...

Zacks Investment Research - 4 months ago

Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 5 months ago

Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure Presented the most robust aggregate dataset of supracho...

GlobeNewsWire - 5 months ago

ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and ...

GlobeNewsWire - 5 months ago

ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...

GlobeNewsWire - 5 months ago

ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and ...

GlobeNewsWire - 6 months ago

- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE - - New intellectual property covers suprachoroidal administration with the...

Seeking Alpha - 6 months ago

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 6 months ago

- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manu...

GlobeNewsWire - 6 months ago

- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 -

GlobeNewsWire - 6 months ago

ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pr...

Zacks Investment Research - 6 months ago

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pr...

Zacks Investment Research - 7 months ago

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pr...

Zacks Investment Research - 8 months ago

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 8 months ago

– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration –

Zacks Investment Research - 9 months ago

Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for t...

Zacks Investment Research - 9 months ago

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 10 months ago

- Management to Host Webcast and Conference Call Today at 8:30 A.M. ET -

GlobeNewsWire - 10 months ago

- Pfizer veteran brings global R&D expertise to Board of Directors - - Pfizer veteran brings global R&D expertise to Board of Directors -

GlobeNewsWire - 10 months ago

ALPHARETTA, Ga., April 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...

Seeking Alpha - 11 months ago

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019.

GlobeNewsWire - 11 months ago

ALPHARETTA, Ga., March 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...

GlobeNewsWire - 11 months ago

– Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in Asia – – Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on...

Zacks Investment Research - 11 months ago

Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

Presentations to Focus on Novel Suprachoroidal Delivery of CLS-AX (axitinib injectable suspension) as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration Presentat...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Clearside Biomedical.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -6.25% and 182.00%, respectively, for the quarter ended September 2019.

GlobeNewsWire - 1 year ago

ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...

Other stocks mentioned: RGNX
GlobeNewsWire - 1 year ago

XIPERE™ presentations continue to demonstrate the potential value to treat uveitis patients XIPERE™ presentations continue to demonstrate the potential value to treat uveitis patients

About CLSD

Clearside Biomedical, a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Industry
Biotechnology
IPO Date
Jun 2, 2016
CEO
George Lasezkay
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
CLSD
Full Company Profile

Financial Performance

In 2019, CLSD's revenue was $2.17 million, an increase of 7,143.33% compared to the previous year's $30,000. Losses were -$30.77 million, -62.85% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 84.93% from the latest price.

Price Target
$6.38
(84.93% upside)
Analyst Consensus: Buy